Status:
WITHDRAWN
Assessment of Primary Androgen Deprivation Therapy for Non-metastatic Prostate Cancer Among Elderly
Lead Sponsor:
University of Medicine and Dentistry of New Jersey
Collaborating Sponsors:
United States Department of Defense
Conditions:
Prostate Cancer
Eligibility:
MALE
75+ years
Brief Summary
The widespread availability of screening coupled with high risks of over diagnosis, over treatment, and a rising risk of dying from competing causes of deaths pose a major challenge for prostate cance...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Diagnosed at age 75 or older.
- Diagnosed with non-metastatic prostate cancer in 1992-1999.
- Enrolled in Medicare for the 12 months before diagnosis for an adequate assessment of baseline comorbidity.
- Enrolled in Medicare Part A and Part B through death or the end of the study period to have an adequate claim history of cancer treatment over the follow-up period.
- Alive for at least 6 months after cancer diagnosis. This criterion will remove men who are diagnosed at death or who are dying and have severe comorbidities, and are therefore poor candidates for 'aggressive' cancer interventions.
- Exclusion criteria:
- Enrolled in Medicare managed care plans during the study period since no Medicare claims are available during the period of enrollment.
- Have other types of cancer. This criterion will ensure that all cancer therapies identified from the Medicare claims are for prostate cancer exclusively.
Exclusion
Key Trial Info
Start Date :
March 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00161252
Start Date
March 1 2005
End Date
December 1 2008
Last Update
September 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08901